Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,050Revenue $M34.6Net Margin (%)-532.1Altman Z-Score-6.5
Enterprise Value $M1,230EPS $-0.9Operating Margin %-393.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-532.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.7Cash flow > EarningsY
Price/Sales25.25-y EBITDA Growth Rate %--Current Ratio3.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-57.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M227ROIC % (ttm)-127.4Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
EXELCharles Brandes 2015-06-30 Buy $2.57 - $4.03
$ 4.5440%New holding25,400
EXELFirst Eagle Investment 2014-06-30 Sold Out $3.22 - $3.8
$ 4.5432%Sold Out0
EXELFirst Eagle Investment 2014-03-31 Reduce-0.01%$3.38 - $8.24
$ 4.54-34%Reduce -65.91%400,000
EXELFirst Eagle Investment 2012-09-30 Add0.02%$4.28 - $6.45
$ 4.54-14%Add 422.58%1,175,800
EXELFirst Eagle Investment 2012-03-31 Add$4.49 - $6.47
$ 4.54-12%Add 125.00%225,000
EXELFirst Eagle Investment 2011-12-31 Buy $3.95 - $7.81
$ 4.54-9%New holding100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
$ 4.54-38%Sold Out0
EXELFirst Eagle Investment 2011-03-31 Sold Out $7.22 - $12.45
$ 4.54-54%Sold Out0
EXELFirst Eagle Investment 2010-12-31 Buy 0.01%$3.98 - $9.08
$ 4.54-20%New holding280,000
EXELFirst Eagle Investment 2009-12-31 Sold Out -0.02%$5.33 - $8
$ 4.54-34%Sold Out0
EXELFirst Eagle Investment 2009-09-30 Buy 0.02%$4.4 - $6.99
$ 4.54-20%New holding274,700
EXELFirst Eagle Investment 2009-06-30 Sold Out -0.01%$4.16 - $5.55
$ 4.54-7%Sold Out0
EXELFirst Eagle Investment 2009-03-31 Reduce$4.32 - $5.85
$ 4.54-5%Reduce -25.67%144,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WILLSEY LANCEDirector 2015-12-11Buy100,000$4.89-7.16view
Lamb PeterEVP, Discovery Research & CSO 2015-10-16Sell51,549$5.8-21.72view
Lamb PeterEVP, Discovery Research & CSO 2015-10-13Sell300,876$5.84-22.26view
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71165.5view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-11.84view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-2.99view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-3.81view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.393.42view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-11.5view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-46.59view

Quarterly/Annual Reports about EXEL:

News about EXEL:

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 

More From Other Websites
Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10 Feb 04 2016
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study Feb 02 2016
Exelixis Rises on Positive Late-Stage Trial Results Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis's Cabozantinib Granted Priority Review in the U.S. Jan 29 2016
Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for... Jan 28 2016
Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority... Jan 28 2016
Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
[video]'Mad Money' Lightning Round: Move on From Broadcom Jan 20 2016
Exelixis upgraded by Leerink Partners Jan 19 2016
Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a... Jan 11 2016
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and... Jan 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)